| 產(chǎn)品編號(hào) | bsm-30099M |
| 英文名稱(chēng) | human CD22 Mouse mAb |
| 中文名稱(chēng) | 小鼠抗人CD22單克隆抗體 |
| 別 名 | B-cell receptor CD22; B cell receptor CD22 precursor; B lymphocyte cell adhesion molecule; BL CAM; BL-CAM; BLCAM; CD 22; CD22 antigen; CD22 molecule; CD22 protein; Leu14; Lyb8; MGC130020; Sialic acid binding immunoglobulin like lectin 2; SIGLEC 2; SIGLEC2; SIGLEC-2; FLJ22814; MGC130020; CD22_HUMAN; B-lymphocyte cell adhesion molecule; Sialic acid-binding Ig-like lectin 2; Siglec-2; T-cell surface antigen Leu-14. |
| 研究領(lǐng)域 | 腫瘤 免疫學(xué) 細(xì)胞表面分子 b-淋巴細(xì)胞 |
| 抗體來(lái)源 | Mouse |
| 克隆類(lèi)型 | Monoclonal |
| 克 隆 號(hào) | HIB22 |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 | Flow-Cyt=1ug/Test
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 91 kDa |
| 檢測(cè)分子量 | 140 |
| 細(xì)胞定位 | 細(xì)胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human CD22 |
| 亞 型 | Mouse IgG1 |
| 純化方法 | affinity purified by Protein G |
| 緩 沖 液 | 0.01M TBS (pH7.4). |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
Predicted to enable CD4 receptor binding activity; protein phosphatase binding activity; and sialic acid binding activity. Involved in B cell activation; negative regulation of B cell receptor signaling pathway; and regulation of endocytosis. Located in early endosome and recycling endosome. [provided by Alliance of Genome Resources, Nov 2021] Function: Mediates B-cell B-cell interactions. May be involved in the localization of B-cells in lymphoid tissues. Binds sialylated glycoproteins; one of which is CD45. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site can be masked by cis interactions with sialic acids on the same cell surface. Upon ligand induced tyrosine phosphorylation in the immune response seems to be involved in regulation of B-cell antigen receptor signaling. Plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules. Subunit: Predominantly monomer of isoform CD22-beta. Also found as heterodimer of isoform CD22-beta and a shorter isoform. Interacts with PTPN6/SHP-1, LYN, SYK, PIK3R1/PIK3R2 and PLCG1 upon phosphorylation. Interacts with GRB2, INPP5D and SHC1 upon phosphorylation. May form a complex with INPP5D/SHIP, GRB2 and SHC1. Subcellular Location: Cell membrane; Single-pass type I membrane protein. Tissue Specificity: B-lymphocytes. Post-translational modifications: Phosphorylation of Tyr-762, Tyr-807 and Tyr-822 are involved in binding to SYK, GRB2 and SYK, respectively. Phosphorylation of Tyr-842 is involved in binding to SYK, PLCG2 and PIK3R1/PIK3R2. Phosphorylated on tyrosine residues by LYN (By similarity). Similarity: Belongs to the immunoglobulin superfamily. SIGLEC (sialic acid binding Ig-like lectin) family. Contains 6 Ig-like C2-type (immunoglobulin-like) domains. Contains 1 Ig-like V-type (immunoglobulin-like) domain. SWISS: P20273 Gene ID: 933 Database links: Entrez Gene: 933 Human Entrez Gene: 12483 Mouse Omim: 107266 Human SwissProt: P20273 Human SwissProt: P35329 Mouse Unigene: 579691 Human Unigene: 260994 Mouse |
| 產(chǎn)品圖片 |
Blank control:Daudi.
Primary Antibody (green line): Mouse Anti-human CD22 antibody (bsm-30099M)
Dilution: 1ug/Test;
Secondary Antibody (white blue line) : Goat anti-mouse IgG-FITC
Dilution: 0.5ug/Test.
Isotype control（orange line）：Normal Rabbit IgG
Protocol
The cells were incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.
|
